When was NEOGAP founded?

NEOGAP was founded in 2016 and raised its 1st funding round 7 years after it was founded.

Where is NEOGAP located?

NEOGAP is headquartered in Stockholm, Sweden.

How many employees does NEOGAP have?

As of May 31, 2026, the latest employee count at NEOGAP is 26.

Is NEOGAP a funded company?

NEOGAP is a funded company, having raised a total of $10.2M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2023.

When was the latest funding round of NEOGAP?

NEOGAP's latest funding was a $***** Series A round on Feb 11, 2026, with participation from 1 investor. Its primary sector is Healthcare IT. In Sweden, the Healthcare IT sector has seen $27.1M in funding in 2026 to date.

Where does NEOGAP rank among its competitors?

NEOGAP ranks 421st amongst 3282 active competitors, of which 1126 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of NEOGAP?

NEOGAP's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

NEOGAP - 2026 Company Profile, Team, Funding & Competitors

NEOGAP is a series A company based in Stockholm (Sweden), founded in 2016 by Hans Gronlund. It operates as a Developer of radiopharmaceuticals for the treatment of cancer. NEOGAP has raised $10.2M in funding from Okomera. The company has 3282 active competitors, including 1126 funded and 772 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of radiopharmaceuticals for the treatment of cancer. The company has pTTL cell therapy product, which targets neoantigens by using proprietary PIOR and patented EpiTCer technologies, targeting neoantigens using immune cells from cancer patients as starting material.

Website: neogap.se
Phone Number: +46 **********

Key Metrics

Founded Year

2016

Location

Stockholm, Sweden

Stage

Series A

Total Funding

$10.2M in 4 rounds

Latest Funding Round

Series A, Feb 11, 2026, $*****

Investors

Okomera & 5 more

Ranked

421^st among 3282 active competitors

Employee Count

26 as on May 31, 2026

Similar Companies

BeiGene & 595 more

View NEOGAP's full profile

NEOGAP has raised a total funding of $10.2M over 4 rounds. Its first funding round was on 2023. Its latest funding round was a Series A round on Feb 11, 2026 for $*****. 1 investor participated in its latest round. NEOGAP has 6 institutional investors.

Here is the list of recent funding rounds of NEOGAP:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 11, 2026	5414629	Series A	1489506	4027515	4056543	7063261
Mar 26, 2024	8899491	Seed	1613790	8611411	4533416	Eureka
Nov 01, 2023	4365139	Grant (prize money)	5927689	3001760	2547464	Europa

Access funding benchmarks and valuations. Sign up today!

View details of NEOGAP's funding rounds and investors

The founders of NEOGAP is Hans Gronlund. Samuel Svensson is the CEO of NEOGAP.

Here are the details of NEOGAP's key team members:

Hans Gronlund: Founder of NEOGAP.
Contact Info: 1 email address
Samuel Svensson: CEO of NEOGAP.

View details of NEOGAP's Founder profiles and Board Members

NEOGAP's employee count trend

NEOGAP has 26 employees as of May 26. Here is NEOGAP's employee count trend over the years:

Uncover NEOGAP's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NEOGAP include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of NEOGAP, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
421st	NEOGAP 2016, Stockholm (Sweden), Series A	Developer of radiopharmaceuticals for the treatment of cancer	$10.2M	Eureka, Northislet & 4 others	55/100